NR 566
MIDTERM AND FINAL EXAM
Advanced Pharmacology for Care of the Family
A 3-credit FNP Specialty Course Questions and Answers
Chamberlain
This Document has NR 566 200 (Actual) Latest questions and answers
1. What pharmacokinetic process describes movement of a drug from the
administration site into systemic circulation?
Answer: Absorption.
Rationale: Absorption is the transfer of a drug from its administration site into the
bloodstream.
2. What pharmacokinetic process describes the movement of a drug from the
bloodstream into tissues?
Answer: Distribution.
Rationale: Distribution determines how a drug moves between plasma and body
tissues.
3. What organ is primarily responsible for hepatic drug metabolism?
Answer: Liver.
Rationale: Hepatic enzymes, particularly the cytochrome P450 system, metabolize
many medications.
4. What is the primary organ responsible for renal drug elimination?
Answer: Kidneys.
Rationale: The kidneys eliminate many drugs and metabolites through glomerular
filtration, secretion, and reabsorption.
5. What does a drug’s half-life represent?
Answer: The time required for the plasma drug concentration to decrease by 50%.
,Rationale: Half-life helps determine dosing intervals and the time required to reach
steady state.
6. Approximately how long does it usually take a drug to reach steady state when
administered repeatedly?
Answer: About 4–5 half-lives.
Rationale: Repeated dosing generally approaches steady-state concentration after
several half-lives.
7. What is pharmacodynamics?
Answer: The study of what a drug does to the body.
Rationale: Pharmacodynamics includes receptor interactions, therapeutic effects,
and adverse effects.
8. What is pharmacokinetics?
Answer: The study of what the body does to a drug.
Rationale: Pharmacokinetics encompasses absorption, distribution, metabolism, and
excretion.
9. What is the primary concern when prescribing renally eliminated medications to
a patient with significant renal impairment?
Answer: Drug accumulation and toxicity.
Rationale: Reduced renal clearance can increase drug concentrations.
10. What is the purpose of therapeutic drug monitoring?
Answer: To maintain drug concentrations within an effective and safe range.
Rationale: Monitoring is particularly useful for medications with narrow therapeutic
indexes.
11. What is a drug’s therapeutic index used to describe?
Answer: The relative margin between therapeutic and toxic doses.
Rationale: A narrow therapeutic index indicates that small concentration changes
can produce toxicity.
12. What is an agonist?
Answer: A substance that binds to a receptor and activates it.
Rationale: Agonists produce receptor-mediated effects by activating receptor
activity.
13. What is an antagonist?
Answer: A substance that binds to a receptor and blocks its activation.
Rationale: Antagonists prevent or reduce the effects of receptor agonists.
14. What is a partial agonist?
Answer: A drug that activates a receptor but produces less-than-maximal activity.
Rationale: Partial agonists can produce therapeutic effects while having a ceiling to
receptor activation.
, 15. Why is pharmacogenomics important in advanced pharmacology?
Answer: It helps predict how genetic variation may influence medication response.
Rationale: Genetic differences can affect drug metabolism, efficacy, and adverse-
effect risk.
16. What enzyme system is responsible for metabolism of many commonly
prescribed medications?
Answer: Cytochrome P450 enzymes.
Rationale: CYP enzymes are major contributors to phase I hepatic drug metabolism.
17. What happens when a strong CYP enzyme inhibitor is administered with a drug
metabolized by that enzyme?
Answer: The substrate drug concentration may increase.
Rationale: Enzyme inhibition reduces metabolism and can increase systemic drug
exposure.
18. What happens when a strong CYP enzyme inducer is administered with a
medication metabolized by that enzyme?
Answer: The medication concentration may decrease.
Rationale: Enzyme induction accelerates metabolism of susceptible drugs.
19. What is a major prescribing concern with polypharmacy?
Answer: Increased risk of drug interactions and adverse drug events.
Rationale: The number of potential medication-related problems increases as
medication burden increases.
20. What is the best general strategy for minimizing inappropriate polypharmacy?
Answer: Regular medication reconciliation and deprescribing when appropriate.
Rationale: Reviewing the indication, benefit, risk, and necessity of each medication
can reduce unnecessary therapy.
21. What is medication reconciliation?
Answer: Comparing a patient’s complete medication list with current orders to
identify discrepancies.
Rationale: Reconciliation helps prevent omissions, duplications, dosing errors, and
interactions.
22. What is the preferred general principle when prescribing medication during
pregnancy?
Answer: Use medication only when the expected maternal or fetal benefit
outweighs potential risk.
Rationale: Pregnancy can alter pharmacokinetics while fetal exposure must also be
considered.
23. Why should pediatric medication dosing generally be individualized by weight or
another validated parameter?
Answer: Children have age- and size-dependent pharmacokinetic differences.
Rationale: Pediatric drug handling differs substantially from adult pharmacology.
MIDTERM AND FINAL EXAM
Advanced Pharmacology for Care of the Family
A 3-credit FNP Specialty Course Questions and Answers
Chamberlain
This Document has NR 566 200 (Actual) Latest questions and answers
1. What pharmacokinetic process describes movement of a drug from the
administration site into systemic circulation?
Answer: Absorption.
Rationale: Absorption is the transfer of a drug from its administration site into the
bloodstream.
2. What pharmacokinetic process describes the movement of a drug from the
bloodstream into tissues?
Answer: Distribution.
Rationale: Distribution determines how a drug moves between plasma and body
tissues.
3. What organ is primarily responsible for hepatic drug metabolism?
Answer: Liver.
Rationale: Hepatic enzymes, particularly the cytochrome P450 system, metabolize
many medications.
4. What is the primary organ responsible for renal drug elimination?
Answer: Kidneys.
Rationale: The kidneys eliminate many drugs and metabolites through glomerular
filtration, secretion, and reabsorption.
5. What does a drug’s half-life represent?
Answer: The time required for the plasma drug concentration to decrease by 50%.
,Rationale: Half-life helps determine dosing intervals and the time required to reach
steady state.
6. Approximately how long does it usually take a drug to reach steady state when
administered repeatedly?
Answer: About 4–5 half-lives.
Rationale: Repeated dosing generally approaches steady-state concentration after
several half-lives.
7. What is pharmacodynamics?
Answer: The study of what a drug does to the body.
Rationale: Pharmacodynamics includes receptor interactions, therapeutic effects,
and adverse effects.
8. What is pharmacokinetics?
Answer: The study of what the body does to a drug.
Rationale: Pharmacokinetics encompasses absorption, distribution, metabolism, and
excretion.
9. What is the primary concern when prescribing renally eliminated medications to
a patient with significant renal impairment?
Answer: Drug accumulation and toxicity.
Rationale: Reduced renal clearance can increase drug concentrations.
10. What is the purpose of therapeutic drug monitoring?
Answer: To maintain drug concentrations within an effective and safe range.
Rationale: Monitoring is particularly useful for medications with narrow therapeutic
indexes.
11. What is a drug’s therapeutic index used to describe?
Answer: The relative margin between therapeutic and toxic doses.
Rationale: A narrow therapeutic index indicates that small concentration changes
can produce toxicity.
12. What is an agonist?
Answer: A substance that binds to a receptor and activates it.
Rationale: Agonists produce receptor-mediated effects by activating receptor
activity.
13. What is an antagonist?
Answer: A substance that binds to a receptor and blocks its activation.
Rationale: Antagonists prevent or reduce the effects of receptor agonists.
14. What is a partial agonist?
Answer: A drug that activates a receptor but produces less-than-maximal activity.
Rationale: Partial agonists can produce therapeutic effects while having a ceiling to
receptor activation.
, 15. Why is pharmacogenomics important in advanced pharmacology?
Answer: It helps predict how genetic variation may influence medication response.
Rationale: Genetic differences can affect drug metabolism, efficacy, and adverse-
effect risk.
16. What enzyme system is responsible for metabolism of many commonly
prescribed medications?
Answer: Cytochrome P450 enzymes.
Rationale: CYP enzymes are major contributors to phase I hepatic drug metabolism.
17. What happens when a strong CYP enzyme inhibitor is administered with a drug
metabolized by that enzyme?
Answer: The substrate drug concentration may increase.
Rationale: Enzyme inhibition reduces metabolism and can increase systemic drug
exposure.
18. What happens when a strong CYP enzyme inducer is administered with a
medication metabolized by that enzyme?
Answer: The medication concentration may decrease.
Rationale: Enzyme induction accelerates metabolism of susceptible drugs.
19. What is a major prescribing concern with polypharmacy?
Answer: Increased risk of drug interactions and adverse drug events.
Rationale: The number of potential medication-related problems increases as
medication burden increases.
20. What is the best general strategy for minimizing inappropriate polypharmacy?
Answer: Regular medication reconciliation and deprescribing when appropriate.
Rationale: Reviewing the indication, benefit, risk, and necessity of each medication
can reduce unnecessary therapy.
21. What is medication reconciliation?
Answer: Comparing a patient’s complete medication list with current orders to
identify discrepancies.
Rationale: Reconciliation helps prevent omissions, duplications, dosing errors, and
interactions.
22. What is the preferred general principle when prescribing medication during
pregnancy?
Answer: Use medication only when the expected maternal or fetal benefit
outweighs potential risk.
Rationale: Pregnancy can alter pharmacokinetics while fetal exposure must also be
considered.
23. Why should pediatric medication dosing generally be individualized by weight or
another validated parameter?
Answer: Children have age- and size-dependent pharmacokinetic differences.
Rationale: Pediatric drug handling differs substantially from adult pharmacology.
